Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background
Response to the anti-IL17 monoclonal antibody secukinumab is heterogeneous, and not all participants respond to treatment. Understanding whether this heterogeneity is driven by genetic variation is a key aim of pharmacogenetics and could influence precision medicine approaches in inflammatory diseas...
Main Authors: | Zhang, K, Shestopaloff, K, Hollis, B, Kwok, C, Hon, C, Hartmann, N, Tian, C, Wozniak, M, Santos, L, West, D, Gardiner, S, Mallon, A-M, Readie, A, Martin, R, Nichols, T, Beste, M, Zierer, J, Ferrero, E, Vandemeulebroecke, M, Jostins-Dean, L |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Cell Press
2023
|
Similar Items
-
A framework for longitudinal latent factor modelling of treatment response in clinical trials with applications to Psoriatic Arthritis and Rheumatoid Arthritis
by: Falck, F, et al.
Published: (2024) -
Axion-like-particle decay in strong electromagnetic backgrounds
by: King, B, et al.
Published: (2019) -
Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis
by: Mallon, A-M, et al.
Published: (2021) -
Infinite processes : background to analysis /
by: 194696 Gardiner, A.
Published: (1982) -
Seismic background noise levels in the Italian strong-motion network
by: S. F. Fornasari, et al.
Published: (2023-10-01)